Why the study?
Diabetes and pre-diabetes are overrepresented and associated with adverse prognosis in PCI patients, making optimal glycaemic control and newer glucose-lowering drugs clinically relevant.
This narrative review summarizes current recommendations for glucose-lowering therapy and glycemic control targets in patients with diabetes undergoing percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
Provides synthesized guidance on post-PCI glycemic management in diabetes; extends prior reviews while leaving optimal targets open to prospective trials.
The number of individuals with diabetes and pre-diabetes is constantly increasing. These conditions are overrepresented in patients undergoing percutaneous coronary intervention and are associated with adverse prognosis. Optimal glycaemic control during an acute coronary syndrome is a relevant factor for the improvement of longer-term outcomes. In addition, the implementation of newer glucose-lowering drugs with proven cardiovascular benefits has a remarkable impact on recurrence of events, hospitalisations for heart failure and mortality. In this narrative review, we outline the current state-of-the art recommendations for glucose-lowering therapy in patients with diabetes undergoing coronary intervention. In addition, we discuss the most recent evidence-based indications for revascularisation in patients with diabetes as well as the targets for glycaemic control post revascularisation. Current treatment goals for concomitant risk factor control are also addressed. Lastly, we acknowledge the presence of knowledge gaps in need of future research.
No takes yet. Share an insight, caveat, or question.
Johansson et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: